SCHEMBL6324332

SCHEMBL6324332

COc1ccc(S(=O)(=O)N(CC(C)C)[C@H](C)CS)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 8/20 0.51
MMP1 P03956 5/20 0.51
KEAP1 Q14145 2/20 0.48
NFE2L2 Q16236 1/20 0.48
MMP8 P22894 3/20 0.47
BMP1 P13497 4/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
MMP7 P09237 1/20 0.44
MMP12 P39900 1/20 0.44
MMP2 P08253 2/20 0.43
MMP3 P08254 2/20 0.43
MMP9 P14780 2/20 0.43
TAS2R14 Q9NYV8 1/20 0.43
HPGD P15428 1/20 0.43
MMP14 P50281 1/20 0.43
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324327 1.00 MMP13 (0.51) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6331630 0.86 MMP13 (0.53) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6331628 0.86 MMP13 (0.53) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6323494 0.82 MMP13 (0.48) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6323497 0.82 MMP13 (0.48) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6330875 0.81 TAS2R14 (0.58) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6323924 0.81 TAS2R14 (0.58) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6323929 0.81 TAS2R14 (0.58) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6323218 0.81 MEN1 (0.61) MMP13MMP1KEAP1NFE2L2MMP8
SCHEMBL6323221 0.81 MEN1 (0.61) MMP13MMP1KEAP1NFE2L2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 MMP13 2/4885MMP1 13/4885KEAP1 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.